+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 37 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.

Age: 18Years - 75YearsAll GendersPhase 2
119 locations
A

Actively Recruiting

Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.

Age: 18Years +All Genders
44 locations
I

Actively Recruiting

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

Age: 18Years - 75YearsAll Genders
132 locations
S

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with ALK gene rearrangement treated with next-generation tyrosine kinase inhibitors TKIs as first-line therapy. This prospective study, part of the national EXPLORE ALK cohort, aims to understand the biological characteristics and resistance mechanisms of this cancer type. It involves patients with stage IIIB or IV NSCLC who are not eligible for curative locoregional treatment and have confirmed ALK rearrangement. The study collects tumor tissue samples at diagnosis and at disease progression, if available, to analyze ALK fusion partners, variants, and co-mutations using RNA sequencing. Blood samples are taken at diagnosis, first tumor evaluation, and disease progression to analyze circulating tumor DNA ctDNA with next-generation sequencing. Treatments studied include alectinib, brigatinib, lorlatinib, and entrectinib, either marketed or under early access programs. Participants provide blood samples and allow use of tumor tissue for centralized biological analyses. Researchers measure progression-free survival up to 72 months as the primary outcome, along with overall survival, response rates, duration of response, ctDNA clearance, and resistance mechanisms associated with treatment and ALK fusion partners. The study involves regular evaluations over several years to monitor treatment outcomes and biological changes.

Age: 18Years +All GendersPhase Not Applicable
46 locations
E

Actively Recruiting

Researchers are studying the effectiveness and safety of lorlatinib in patients with untreated ALK-positive non-small-cell lung carcinoma NSCLC. This research is conducted in a French real-world setting and sponsored by Pfizer. The study aims to assess how lorlatinib performs as a treatment option for this specific type of lung cancer. Participants will receive lorlatinib as a single-agent oral treatment at a dose of 100 mg daily. The study is designed as a single-group trial where patients continuously take lorlatinib. The treatment and observation period includes assessments up to 25 months, during which various outcomes such as progression-free survival, overall survival, response rates, and treatment duration will be evaluated. During the study, participants will be monitored regularly with imaging tests like CT scans and brain MRIs before starting treatment. Researchers will track treatment adherence, symptom changes, adverse events, and resistance mechanisms. Patient-reported outcomes and quality of life questionnaires will be collected at multiple time points up to 48 months. Safety and effectiveness measures will guide the ongoing evaluation, with follow-up visits scheduled throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
32 locations
P

Actively Recruiting

Researchers are evaluating mechanical ventilation strategies and the timing of muscle relaxation in patients with moderate to severe Acute Respiratory Distress Syndrome ARDS. The study aims to test personalized approaches for setting Positive End-Expiratory Pressure PEEP based on lung recruitability and whether early use of neuromuscular blocking agents NMBAs during prone positioning improves survival compared to rescue use. This trial addresses the lack of specific treatments for ARDS and focuses on improving survival by optimizing ventilation methods. Participants will be assigned to different ventilation strategies routine care with minimal lung distension using low tidal volume and conservative PEEP, routine care with maximal lung recruitment adjusting tidal volume and PEEP to maintain safe plateau pressures, or a personalized PEEP strategy based on a PEEP responsiveness test. Additionally, the study compares early systematic use of NMBAs during prone positioning to rescue use. Two randomizations occur first for ventilation strategy and second for NMBA timing. During the study, participants will undergo mechanical ventilation with assigned strategies, and researchers will monitor oxygenation, respiratory parameters, organ function scores, and mortality over time. Assessments include arterial blood gases, tidal volumes, respiratory rates, and organ failure evaluations at multiple time points up to one year. The primary outcome is 28-day all-cause mortality. Safety and long-term outcomes such as disability, cognitive function, quality of life, and return to work status will also be evaluated throughout the follow-up period.

Age: 18Years +All GendersPhase Not Applicable
29 locations
S

Actively Recruiting

This research aims to evaluate the use of implantable cardioverter defibrillators ICD for preventing sudden cardiac death in patients aged 70 years and older who have an ICD indication for primary prevention. It specifically compares whether heart failure optimal therapy alone HFOT is not worse than combining HFOT with ICD implantation regarding overall survival at 48 months after randomization. The study addresses the lack of clear evidence about the benefit of ICDs in the elderly and seeks to understand if avoiding ICD implantation can reduce device-related complications and healthcare costs. Participants are randomly assigned to one of two groups one group receives heart failure optimal therapy without ICD implantation, and the other receives optimal medical therapy plus ICD implantation. ICD devices used are any CE-marked brand available and reimbursed in the French market, implanted at the discretion of the local investigator. The study follows patients for four years after randomization, monitoring survival and health outcomes. During the study, participants undergo regular assessments including heart failure evaluations and quality of life questionnaires at multiple intervals up to 48 months. Researchers measure overall survival as the primary outcome and track cardiovascular mortality, sudden cardiac death, hospitalizations, ICD-related complications, and quality of life scores as secondary outcomes. The trial includes follow-up visits to monitor health status, treatment adherence, and complications to provide comprehensive data on the long-term impact of these treatment strategies.

Age: 70Years +All GendersPhase Not Applicable
19 locations
C

Actively Recruiting

This research aims to collect real-life clinical data to evaluate the safety and performance of medical devices used in treating prostate cancer. Specifically, it focuses on patients who have received High Intensity Focused Ultrasound HIFU treatment using the Focal One device. The study is both prospective and retrospective, gathering information over several years to better understand treatment outcomes. Participants are men treated for prostate cancer with the Focal One HIFU device. The study involves monitoring from the time of HIFU treatment up to five years afterward. Throughout this period, data will be collected on prostate-specific antigen PSA levels, prostate MRI findings for local cancer recurrence, biopsy results, and any retreatment rates to assess ongoing treatment safety and effectiveness. Participants will contribute data over a follow-up period extending up to five years after their HIFU treatment. Researchers will collect and review clinical information, imaging results, and laboratory tests. The primary focus is on monitoring safety outcomes related to the HIFU procedure. This long-term observation aims to provide a comprehensive understanding of treatment effects and patient health over time.

All AgesMALE
5 locations
C

Actively Recruiting

Researchers are studying men over 40 years old with benign prostatic hyperplasia BPH who need surgery to improve urinary symptoms. The trial compares two types of prostate surgery a conventional endoscopic resection and a newer partial surgery that aims to preserve ejaculation function. This study explores whether the partial surgery can maintain ejaculation without reducing the relief of urinary symptoms, which is important because ejaculatory dysfunction often lowers quality of life after surgery. Participants are randomly assigned to one of two surgical groups. One group undergoes conventional endoscopic resection of the prostate, while the other receives a partial endoscopic resection that preserves the apex area near the veru montanum. The study is single-blinded, meaning patients do not know which surgery they receive. The main focus is on symptom improvement measured by the International Prostatic Symptom Score IPSS six months after surgery. During the study, men will have evaluations at 1, 3, 6, 12, and 36 months after surgery. These assessments include urinary symptoms, ejaculation and overall sexual life, urinary flow rates, and any surgery-related complications. The trial tracks these outcomes to understand the benefits and effects of each surgical method over time. Patients are expected to comply with scheduled visits and provide informed consent before participating.

Age: 40Years +MALEPhase Not Applicable
17 locations

1-10 of 37

1